Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 14, 2016 2:17 AM ET


Company Overview of Ritter Pharmaceuticals, Inc.

Company Overview

Ritter Pharmaceuticals, Inc. develops therapeutic products for treatment of inflammatory, gastrointestinal, and metabolic diseases. Its product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. RP-G28 has been studied in a Phase 2a clinical trial. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September, 2008. Ritter Pharmaceuticals, In...

1801 Century Park East

Suite 1820

Los Angeles, CA 90067

United States

Founded in 2004

5 Employees





Key Executives for Ritter Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 55
Total Annual Compensation: $348.7K
Founder, President and Director
Age: 32
Total Annual Compensation: $259.3K
Co-Founder, Executive Chairman and Chief Strategic Officer
Age: 65
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2015.

Ritter Pharmaceuticals, Inc. Key Developments

Ritter Pharmaceuticals Appoints William J. Sandborn, M.D. to Medical Advisory Board

Ritter Pharmaceuticals, Inc. announced the appointment of William J. Sandborn, M.D. to its Medical Advisory Board. Dr. Sandborn serves as the Chief, Division of Gastroenterology and Director at University of California San Diego Inflammatory Bowel Disease Center and Professor of Clinical Medicine. From April 1993 to December 2010, Dr. Sandborn was head of the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN and from January 2011 to present, the Division of Gastroenterology, University of California.

Ritter Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Third Quarter Ended September 30, 2015

Ritter Pharmaceuticals, Inc. reported unaudited earnings results for the third quarter ended September 30, 2015. For the third quarter of 2015, the company reported a net loss attributable to common stockholders of approximately $3.1 million compared to a net loss of approximately $0.4 million for the third quarter of 2014. Basic and diluted net loss per share was $0.40 for the compared to basic and diluted net loss per share of $0.92 for the same period in 2014. Operating loss was $3.1 million against $0.3 million a year ago.

Ritter Pharmaceuticals, Inc. Announces Executive Changes

Effective November 1, 2015, Samuel Lynn will cease serving as the Chief Financial Officer of Ritter Pharmaceuticals, Inc. Ellen Mochizuki, Vice President, Finance of the Company, will serve as sole principal financial officer. The Company previously reported the hiring of Ms. Mochizuki effective September 18, 2015.

Similar Private Companies By Industry

Company Name Region
Firma Medical, LLC United States
PHIGENIX, Inc. United States
Ndal Manufacturing Industries, Inc. United States
Vireo Health LLC United States
Noven Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Private Placement
December 18, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ritter Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at